L-carnitine inhibits a subset of platelet activation responses in chronic uraemia

Nephrology Dialysis Transplantation

Volumn 22, Issue 9, 2007, Pages 2623-2629

  Bonomini, Mario ^a,d   Sirolli, Vittorio ^a   Dottori, Secondo ^b   Amoroso, Luigi ^a   Di Liberato, Lorenzo ^a   Arduini, Arduino ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b Sigma Tau SpA   (Italy)

^c Iperboreal Pharma Srl ^*  (Italy)

^d Clinica Nefrologica Emodialisi Ospedale Clinicizzato 'SS Annunziata'   (Italy)

Author keywords

Caspase; End stage renal disease; L carnitine; Phosphatidylserine; Platelet; Uraemia

Indexed keywords

CARNITINE; CASPASE 3; CASPASE 7; CASPASE 8; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PLACEBO; RHODAMINE; THROMBIN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; MALE; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THROMBOCYTE ACTIVATION; THROMBOPHILIA; UREMIA;

AGED; BLOOD PLATELETS; CARNITINE; CASPASES; CHRONIC DISEASE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; P-SELECTIN; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; UREMIA;

EID: 34548423731     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm212     Document Type: Article

References (27)

1. Hakim RM, Schafer AI. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 1985; 78: 575-580
2. Himmelfarb J, Holbrook D, McMonagle E, Ault K. Increased reticulated platelets in dialysis patients. Kidney Int 1997; 51: 834-839
3. Sirolli V, Strizzi L, Di Stante S, Robuffo I, Procopio A, Bonomini M. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Haemost 2001; 86: 834-839
4. Bonomini M, Dottori S, Amoroso A, Arduini A, Sirolli V. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 2: 1-8
5. Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance hemodialysis. Nephron 1998; 80: 380-400
6. Bonomini M, Stuard S, Carreno M-P et al. Neutrophil reactive oxygen species production during hemodialysis: Role of activated platelet adhesion to neutrophils through p-selectin. Nephron 1997; 75: 402-411
7. Hemmendinger S, Newmann MR, Beretz A et al. Mitogenic activity on human arterial smooth muscle cells is increased in the plasma of patients undergoing hemodialysis with cuprophane membranes. Nephron 1989; 53: 147-151
8. Fox JEB. Platelet activation: New aspects. Haemostasis 1996; 26: 102-131
9. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132
10. Kuypers FA. Phospholipid asymmetry in health and disease. Curr Opin Hematol 1998; 5: 122-131
11. Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial 2003; 16: 245-256
12. Shcherbina A, Remold-O'Donnell E. Role of caspase in a subset of human platelet activation responses. Blood 1999; 93: 4222-4231
13. Perrotta PL, Perrotta CC, Snyder EC. Apoptotic activity in stored human platelets. Transfusion 2003; 45: 526-535
14. Cohen Z, Wilson J, Ritter L, McDonagh P. Caspase inhibition decreases both platelet phosphatidylserine exposure and aggregation. Thromb Res 2004; 13: 387-393
15. Wolf BB, Goldstein JC, Stennicke HR et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 1999; 94: 1683-1692
16. Sweeney JD, Kouttab NM, Arduini A. L-carnitine improves pH and decreases surface phosphatidylserine expression in extended stored apheresis platelets. J Clin Apher 2004; 19: 98-102
17. Mutomba MC, Yuan H, Konyavko M et al. Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine. FEBS Lett 2000; 478: 19-25
18. Tallarico C, Pace S, Longo A. Quantitation of L-carnitine, acetyl-L-carnitine, propionyl-L-carnitine and their deuterated analogues by high performance liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 1998; 12: 403-409
19. Talanian RV, Quinlan C, Trautz S et al. Substrate specificities of caspase family proteases. J Biol Chem 1997; 272: 9677-9682
20. Hug H, Los M, Hirt W, Debatin K-M. Rhodamine 110-linked amino acids and peptides as substrates to measure caspase activity upon apoptosis induction in intact cells. Biochemistry 1999; 38: 13906-13911
21. Stenberg PE, McEver RP, Shuman MA et al. A platelet alpha granule membrane protein (GMP140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-885
22. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A, for the CHIEF investigators.Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis 2001; 37: 1018-1028
23. Tein I. Carnitine transport: Pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 2003; 26: 147-169
24. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003; 42: 941-967
25. Sweeney JD, Blair AJ, Cheves DA, Dottori S, Arduini A. L-carnitine decreases glycolysis in liquid-stored platelets. Transfusion 2000; 40: 1313-1319
26. Weschler A, Aviram M, Levin M, Better OS, Brook JG. High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron 1984; 38: 120-124
27. Bellinghieri G, Savica V, Barbera CM et al. L-carnitine and platelet aggregation in uremic patients subjected to hemodialysis. Nephron 1990; 55: 28-32